Peter Voorhees, MD

Peter Voorhees, MD, a myeloma specialist at Levine Cancer Institute, discusses the latest data for the use of pomalidomide (Pomalyst)-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.

There have been several randomized clinical trials that have demonstrated superiority of pomalidomide-based combinations, Voorhees says. The phase II ELOQUENT-3 trial, in particular, looked at the combination of pomalidomide plus dexamethasone with or without elotuzumab (Empliciti). Results showed that patients had a higher likelihood of responding to the 3-drug regimen as compared with the 2-drug combination, and the depth of response also improved with the addition of elotuzumab. This translated to a significant improvement in median progression-free survival (PFS).

FDA approval of elotuzumab in combination with pomalidomide and low-dose dexamethasone

for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapies.

In the randomized phase III ICARIA-MM trial, presented at the 2019 ASCO Annual Meeting,

the triplet regimen of pomalidomide, dexamethasone, and isatuximab also led to similar findings

Videos

Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.

Pomalidomide-Based Triplets Improve Responses in Relapsed/Refractory Multiple Myeloma

Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab (Darzalex) to the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Dara-RVd) in patients with multiple myeloma.

In previous trials, RVd induction therapy performed well for both patients with transplant eligible disease as well as transplant ineligible, Voorhees says. In addition, the IFM 2009 trial showed that lenalidomide induction followed by transplant with lenalidomide consolidation and 1 year of lenalidomide maintenance demonstrated a complete response rate of 60% and median progression-free survival of 50 months.

Peter Voorhees, MD, investigator, department of hematologic oncology &amp; blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Rationale for Adding Daratumumab to RVd in Multiple Myeloma

Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma. 


Peter Voorhees, MD | Authors

Articles

Pomalidomide-Based Triplets Improve Responses in Relapsed/Refractory Multiple Myeloma

Rationale for Adding Daratumumab to RVd in Multiple Myeloma

Daratumumab for the Treatment of Patients With Multiple Myeloma